The DOI matches its Crossref record; 188 of the 188 references it cites were found in a registry or an index.
Endocrine resistance in breast cancer – An overview and update
Open accessAbstract
Tumors that express detectable levels of the product of the ESR1 gene (estrogen receptor-α; ERα) represent the single largest molecular subtype of breast cancer. More women eventually die from ERα+ breast cancer than from either HER2+ disease (almost half of which also express ERα) and/or from triple negative breast cancer (ERα-negative, progesterone receptor-negative, and HER2-negative). Antiestrogens and aromatase inhibitors are largely indistinguishable from each other in their abilities to improve overall survival and almost 50% of ERα+ breast cancers will eventually fail one or more of these endocrine interventions. The precise reasons why these therapies fail in ERα+ breast cancer remain largely unknown. Pharmacogenetic explanations for Tamoxifen resistance are controversial. The role of ERα mutations in endocrine resistance remains unclear. Targeting the growth factors and oncogenes most strongly correlated with endocrine resistance has proven mostly disappointing in their abilities to improve overall survival substantially, particularly in the metastatic setting. Nonetheless, there are new concepts in endocrine resistance that integrate molecular signaling, cellular metabolism, and stress responses including endoplasmic reticulum stress and the unfolded protein response (UPR) that provide novel insights and suggest innovative therapeutic targets. Encouraging evidence that drug combinations with CDK4/CDK6 inhibitors can extend recurrence free survival may yet translate to improvements in overall survival. Whether the improvements seen with immunotherapy in other cancers can be achieved in breast cancer remains to be determined, particularly for ERα+ breast cancers. This review explores the basic mechanisms of resistance to endocrine therapies, concluding with some new insights from systems biology approaches further implicating autophagy and the UPR in detail, and a brief discussion of exciting new avenues and future prospects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Tumour heterogeneity and cancer cell plasticity
Meacham, C. E., & Morrison, S. J. (2013) · Nature · doi:10.1038/nature12624 · Cited by 2,446
Prognostic and predictive factors in breast cancer by immunohistochemical analysis.
Allred, D. C., Harvey, J. M., Berardo, M. D., & Gm, C. (1998) · PubMed · Cited by 2,143
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Holmgren, L., O'Reilly, M. S., & Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0295-149 · Cited by 1,878
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70257-6 · Cited by 1,674
AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian Cancer
Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M., Guan, X.-Y., Sauter, G., Kallioniemi, O.-P., Trent, J. M., & Meltzer, P. S. (1997) · Science · doi:10.1126/science.277.5328.965 · Cited by 1,639
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
Molecular characterization of the tumor microenvironment in breast cancer
Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., Porter, D., Hu, M., Chin, L., Richardson, A., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.010 · Cited by 1,299
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Johnston, S., Pippen, J., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., Gomez, H. L., Romieu, G., Manikhas, A., Kennedy, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3734 · Cited by 1,025
Heterogeneity in breast cancer
Polyak, K. (2011) · Journal of Clinical Investigation · doi:10.1172/jci60534 · Cited by 1,006
An updated review of environmental estrogen and androgen mimics and antagonists
Sonnenschein, C., & Soto, A. M. (1998) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(98)00027-2 · Cited by 990
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967
Kohler, B. A., Sherman, R. L., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K. A., Boscoe, F. P., Cronin, K. A., Lake, A., Noone, A.-M., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv048 · Cited by 915
Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
Yu, M., Bardia, A., Aceto, N., Bersani, F., Madden, M. W., Donaldson, M. C., Desai, R., Zhu, H., Comaills, V., Zheng, Z., et al. (2014) · Science · doi:10.1126/science.1253533 · Cited by 913
Howell, A. (1998) · PubMed · Cited by 901
The pharmacology and clinical uses of tamoxifen
Furr, B. J. A., & Jordan, V. C. (1984) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(84)90043-3 · Cited by 864
Stearns, V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg108 · Cited by 850
Kaufman, B., Mackey, J. R., Clemens, M. R., Bapsy, P. P., Vaid, A., Wardley, A., Tjulandin, S., Jahn, M., Lehle, M., Feyereislova, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6847 · Cited by 843
Proliferation Marker Ki-67 in Early Breast Cancer
Urruticoechea, A., Smith, I. E., & Dowsett, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.501 · Cited by 837
Hershman, D. L., Kushi, L. H., Shao, T., Buono, D., Kershenbaum, A., Tsai, W.-Y., Fehrenbacher, L., Lin Gomez, S., Miles, S., & Neugut, A. I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9655 · Cited by 828
Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
Dowsett, M., Cuzick, J., Ingle, J., Coates, A., Forbes, J., Bliss, J., Buyse, M., Baum, M., Buzdar, A., Colleoni, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1274 · Cited by 813
Lippman, M. E., Bolan, G., & Huff, K. K. (1976) · PubMed · Cited by 810
Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. E., Giordano, S. H., Hudis, C. A., Malin, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3756 · Cited by 796
Osborne, C. K., Bardou, V., Hopp, T. A., Chamness, G. C., Hilsenbeck, S. G., Fuqua, S. A. W., Wong, J., Allred, D. C., Clark, G. M., & Schiff, R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.353 · Cited by 786
Burstein, H. J., Temin, S., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. E., Giordano, S. H., Hudis, C. A., Rowden, D., Solky, A. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.2258 · Cited by 786
A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474
Cole, M. P., Jones, C. T. A., & Todd, I. D. H. (1971) · British Journal of Cancer · doi:10.1038/bjc.1971.33 · Cited by 701
Jeselsohn, R., Yelensky, R., Buchwalter, G., Frampton, G., Meric-Bernstam, F., Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Perez-Fidalgo, J. A., Cristofanilli, M., Gómez, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2332 · Cited by 674
Howell, A., Robertson, J. F. R., Quaresma Albano, J., Aschermannova, A., Mauriac, L., Kleeberg, U. R., Vergote, I., Erikstein, B., Webster, A., & Morris, C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.057 · Cited by 671
Natural Cell-mediated Immunity Against Tumors
(1980) · Elsevier eBooks · doi:10.1016/b978-0-123-41350-5.x5001-4 · Cited by 665
Progesterone receptor modulates ERα action in breast cancer
Mohammed, H., Russell, I. A., Stark, R., Rueda, O. M., Hickey, T. E., Tarulli, G. A., Serandour, A. A., Birrell, S. N., Bruna, A., Saadi, A., et al. (2015) · Nature · doi:10.1038/nature14583 · Cited by 659
Ellis, M. J., Tao, Y., Luo, J., A'Hern, R., Evans, D. B., Bhatnagar, A. S., Chaudri Ross, H. A., von Kameke, A., Miller, W. R., Smith, I., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn309 · Cited by 653
Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8415 · Cited by 636
Li, S., Shen, D., Shao, J., Crowder, R., Liu, W., Prat, A., He, X., Liu, S., Hoog, J., Lu, C., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.022 · Cited by 626
Clarke, R., Ressom, H. W., Wang, A., Xuan, J., Liu, M. C., Gehan, E. A., & Wang, Y. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2294 · Cited by 603
Self-citationDynamics of genomic clones in breast cancer patient xenografts at single-cell resolution
Eirew, P., Steif, A., Khattra, J., Ha, G., Yap, D., Farahani, H., Gelmon, K., Chia, S., Mar, C., Wan, A., et al. (2015) · Nature · doi:10.1038/nature13952 · Cited by 598
Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential
Lee, A. S. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3701 · Cited by 587
Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome
Venet, D., Dumont, J. E., & Detours, V. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002240 · Cited by 586
Structural Overview of the Nuclear Receptor Superfamily: Insights into Physiology and Therapeutics
Huang, P., Chandra, V., & Rastinejad, F. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135917 · Cited by 533
Powell, A. A., Talasaz, A. H., Zhang, H., Coram, M. A., Reddy, A., Deng, G., Telli, M. L., Advani, R. H., Carlson, R. W., Mollick, J. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033788 · Cited by 531
Prognostic and predictive value of PDL1 expression in breast cancer
Sabatier, R., Finetti, P., Mamessier, E., Adelaide, J., Chaffanet, M., Ali, H. R., Viens, P., Caldas, C., Birnbaum, D., & Bertucci, F. (2015) · Oncotarget · doi:10.18632/oncotarget.3216 · Cited by 508
Weigelt, B., Baehner, F. L., & Reis‐Filho, J. S. (2010) · The Journal of Pathology · doi:10.1002/path.2648 · Cited by 482
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling
Clarke, R., Liu, M. C., Bouker, K. B., Gu, Z., Lee, R. Y., Zhu, Y., Skaar, T. C., Gomez, B., O'Brien, K., Wang, Y., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206937 · Cited by 478
Self-citationAntiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover.
Dauvois, S., Danielian, P. S., White, R., & Parker, M. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.4037 · Cited by 465
Johnson, M. D., Zuo, H., Lee, K.-H., Trebley, J. P., Rae, J. M., Weatherman, R. V., Desta, Z., Flockhart, D. A., & Skaar, T. C. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000025406.31193.e8 · Cited by 456
Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
Miller, T. W., Balko, J. M., & Arteaga, C. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4879 · Cited by 413
Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance
Clarke, R., Leonessa, F., Welch, J. N., & Skaar, T. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01479-0 · Cited by 397
Self-citationMerenbakh-Lamin, K., Ben-Baruch, N., Yeheskel, A., Dvir, A., Soussan-Gutman, L., Jeselsohn, R., Yelensky, R., Brown, M., Miller, V. A., Sarid, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1197 · Cited by 393
Growth Factors in Breast Cancer
DICKSON, R. B., & LIPPMAN, M. E. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-5-559 · Cited by 388
Dong, D., Ni, M., Li, J., Xiong, S., Ye, W., Virrey, J. J., Mao, C., Ye, R., Wang, M., Pen, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2950 · Cited by 375
Loi, S., Haibe-Kains, B., Majjaj, S., Lallemand, F., Durbecq, V., Larsimont, D., Gonzalez-Angulo, A. M., Pusztai, L., Symmans, W. F., Bardelli, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907011107 · Cited by 356
van Anken, E., Romijn, E. P., Maggioni, C., Mezghrani, A., Sitia, R., Braakman, I., & Heck, A. J. R. (2003) · Immunity · doi:10.1016/s1074-7613(03)00024-4 · Cited by 353
Chakrabarty, A., Sánchez, V., Kuba, M. G., Rinehart, C., & Arteaga, C. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018001108 · Cited by 347
De Laurentiis, M., Arpino, G., Massarelli, E., Ruggiero, A., Carlomagno, C., Ciardiello, F., Tortora, G., D'Agostino, D., Caputo, F., Cancello, G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2569 · Cited by 340
Breast cancer intra-tumor heterogeneity
Martelotto, L. G., Ng, C. K., Piscuoglio, S., Weigelt, B., & Reis-Filho, J. S. (2014) · Breast Cancer Research · doi:10.1186/bcr3658 · Cited by 332
Robertson, J. F. R., Osborne, C. K., Howell, A., Jones, S. E., Mauriac, L., Ellis, M., Kleeberg, U. R., Come, S. E., Vergote, I., Gertler, S., et al. (2003) · Cancer · doi:10.1002/cncr.11468 · Cited by 315
Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer
Ciruelos Gil, E. M. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.03.004 · Cited by 314
Fu, Y., Li, J., & Lee, A. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4594 · Cited by 304
López‐Knowles, E., O'Toole, S. A., McNeil, C. M., Millar, E. K. A., Qiu, M. R., Crea, P., Daly, R. J., Musgrove, E. A., & Sutherland, R. L. (2010) · International Journal of Cancer · doi:10.1002/ijc.24831 · Cited by 302
Estrogen-Induced Factors of Breast Cancer Cells Partially Replace Estrogen to Promote Tumor Growth
Dickson, R. B., McManaway, M. E., & Lippman, M. E. (1986) · Science · doi:10.1126/science.3715461 · Cited by 267
Creighton, C. J., Fu, X., Hennessy, B. T., Casa, A. J., Zhang, Y., Gonzalez-Angulo, A. M., Lluch, A., Gray, J. W., Brown, P. H., Hilsenbeck, S. G., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2594 · Cited by 258
Controversies in clinical cancer dormancy
Uhr, J. W., & Pantel, K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106613108 · Cited by 251
Lai, A., Kahraman, M., Govek, S., Nagasawa, J., Bonnefous, C., Julien, J., Douglas, K., Sensintaffar, J., Lu, N., Lee, K.-J., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00054 · Cited by 247
Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype
Almog, N., Ma, L., Raychowdhury, R., Schwager, C., Erber, R., Short, S., Hlatky, L., Vajkoczy, P., Huber, P. E., Folkman, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2590 · Cited by 240
Barton, V. N., D'Amato, N. C., Gordon, M. A., Lind, H. T., Spoelstra, N. S., Babbs, B. L., Heinz, R. E., Elias, A., Jedlicka, P., Jacobsen, B. M., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0926 · Cited by 239
Stanway, S. J., Purohit, A., Woo, L. W. L., Sufi, S., Vigushin, D., Ward, R., Wilson, R. H., Stanczyk, F. Z., Dobbs, N., Kulinskaya, E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1996 · Cited by 238
Ju, Y. H., Doerge, D. R., Allred, K. F., Allred, C. D., & Helferich, W. G. (2002) · PubMed · Cited by 235
“Translating” Tumor Hypoxia: Unfolded Protein Response (UPR)–Dependent and UPR-Independent Pathways
Koumenis, C., & Wouters, B. G. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0150 · Cited by 228
Chloroquine Inhibits Autophagy to Potentiate Antiestrogen Responsiveness in ER+ Breast Cancer
Cook, K. L., Wärri, A., Soto-Pantoja, D. R., Clarke, P. A., Cruz, M. I., Zwart, A., & Clarke, R. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3227 · Cited by 226
Self-citationCrowder, R. J., Phommaly, C., Tao, Y., Hoog, J., Luo, J., Perou, C. M., Parker, J. S., Miller, M. A., Huntsman, D. G., Lin, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4450 · Cited by 218
Clarke, R., Cook, K. L., Hu, R., Facey, C. O. B., Tavassoly, I., Schwartz, J. L., Baumann, W. T., Tyson, J. J., Xuan, J., Wang, Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3213 · Cited by 217
Self-citationMolecular Classification of Breast Cancer: Limitations and Potential
Pusztai, L., Mazouni, C., Anderson, K., Wu, Y., & Symmans, W. F. (2006) · The Oncologist · doi:10.1634/theoncologist.11-8-868 · Cited by 214
Karali, E., Bellou, S., Stellas, D., Klinakis, A., Murphy, C., & Fotsis, T. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.03.022 · Cited by 208
Gee, J. M. W., Ellis, I. O., Robertson, J. F. R., Willsher, P., McClelland, R. A., Hewitt, K. N., Blamey, R. W., & Nicholson, R. I. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640410 · Cited by 204
Smith, I. E., Walsh, G., Skene, A., Llombart, A., Mayordomo, J. I., Detre, S., Salter, J., Clark, E., Magill, P., & Dowsett, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6578 · Cited by 201
Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer
Anbalagan, M., & Rowan, B. G. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.01.016 · Cited by 194
Estrogen receptor mutations in tamoxifen-resistant breast cancer.
Karnik, P. S., Kulkarni, S., Liu, X.-P., Budd, G. T., & Bukowski, R. M. (1994) · PubMed · Cited by 192
Pereira, E. R., Frudd, K., Awad, W., & Hendershot, L. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.507194 · Cited by 191
Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells
Tyson, J. J., Baumann, W. T., Chen, C., Verdugo, A., Tavassoly, I., Wang, Y., Weiner, L. M., & Clarke, R. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3081 · Cited by 189
Self-citationSamaddar, J. S., Gaddy, V. T., Duplantier, J., Thandavan, S. P., Shah, M., Smith, M. J., Browning, D., Rawson, J., Smith, S. B., Barrett, J. T., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0447 · Cited by 189
Gomez, B. P., Riggins, R. B., Shajahan, A. N., Klimach, U., Wang, A., Crawford, A. C., Zhu, Y., Zwart, A., Wang, M., & Clarke, R. (2007) · The FASEB Journal · doi:10.1096/fj.06-7990com · Cited by 188
Self-citationMaycotte, P., Gearheart, C. M., Barnard, R., Aryal, S., Mulcahy Levy, J. M., Fosmire, S. P., Hansen, R. J., Morgan, M. J., Porter, C. C., Gustafson, D. L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3470 · Cited by 185
Expression of cytochromes P450 in human breast tissue and tumors.
Huang, Z., Fasco, M. J., Figge, H. L., Keyomarsi, K., & Kaminsky, L. S. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07451-3 · Cited by 184
Paradoxical Dependencies of Tumor Dormancy and Progression on Basic Cell Kinetics
Enderling, H., Anderson, A. R. A., Chaplain, M. A. J., Beheshti, A., Hlatky, L., & Hahnfeldt, P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2115 · Cited by 181
Davies, M. P. A., Barraclough, D. L., Stewart, C., Joyce, K. A., Eccles, R. M., Barraclough, R., Rudland, P. S., & Sibson, D. R. (2008) · International Journal of Cancer · doi:10.1002/ijc.23479 · Cited by 177
Long, X., & Nephew, K. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510809200 · Cited by 169
Tackling the Diversity of Triple-Negative Breast Cancer
Turner, N. C., & Reis-Filho, J. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0915 · Cited by 166
Activation and clinical significance of the unfolded protein response in breast cancer
Scriven, P., Coulson, S. G., Haines, R., Balasubramanian, S. P., Cross, S. S., & Wyld, L. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605365 · Cited by 163
Cook, K. L., Shajahan, A. N., Wärri, A., Jin, L., Hilakivi-Clarke, L. A., & Clarke, R. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0269 · Cited by 161
Self-citationGee, J. M. W., Robertson, J. F. R., Ellis, I. O., Willsher, P., McClelland, R. A., Hoyle, H. B., Kyme, S. R., Finlay, P., Blamey, R. W., & Nicholson, R. I. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590508 · Cited by 160
Ariazi, E. A., Cunliffe, H. E., Lewis-Wambi, J. S., Slifker, M. J., Willis, A. L., Ramos, P., Tapia, C., Kim, H. R., Yerrum, S., Sharma, C. G. N., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115188108 · Cited by 159
Estrogen Receptor Mutations and Changes in Downstream Gene Expression and Signaling
Barone, I., Brusco, L., & Fuqua, S. A. W. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1753 · Cited by 159
Side effects of aromatase inhibitors versus tamoxifen: the patients’ perspective
Garreau, J. R., DelaMelena, T., Walts, D., Karamlou, K., & Johnson, N. (2006) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2006.06.018 · Cited by 158
The Predictive Value of HER2 in Breast Cancer
Piccart, M. J., Lohrisch, C. A., Leo, A. D., & Larsimont, D. (2001) · Oncology · doi:10.1159/000055405 · Cited by 155
Marcom, P. K., Isaacs, C. J., Harris, L. N., Wong, Z. W., Kommareddy, A., Novielli, N., Mann, G., Tao, Y., & Ellis, M. J. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9307-8 · Cited by 154
Dong, D., Stapleton, C. J., Luo, B., Xiong, S., Ye, W., Zhang, Y., Jhaveri, N., Zhu, G., Ye, R., Liu, Z., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3151 · Cited by 148
Lacroix, M., & Leclercq, G. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2004.02.021 · Cited by 142
Autophagy facilitates the progression of ERα-positive breast cancer cells to antiestrogen resistance
Schoenlein, P., Periyasamy‐Thandavan, S., Samaddar, J. S., Jackson, W., & Barrett, J. (2009) · Autophagy · doi:10.4161/auto.5.3.7784 · Cited by 138
Clinical significance of estrogen receptor phosphorylation
Murphy, L. C., Seekallu, S. V., & Watson, P. H. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0070 · Cited by 137
Molecular and pharmacological aspects of antiestrogen resistance
Clarke, R. C., Skaar, T. C., Bouker, K. B., Davis, N., Lee, Y. R., Welch, J. N., & Leonessa, F. (2001) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00193-x · Cited by 135
Self-citationColler, J. K., Krebsfaenger, N., Klein, K., Endrizzi, K., Wolbold, R., Lang, T., Nussler, A. K., Neuhaus, P., Zanger, U. M., Eichelbaum, M. F., et al. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01614.x · Cited by 132
Ligand-independent activation of estrogen receptor by XBP-1
Ding, L. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg731 · Cited by 131
Mackay, A. G., Weigelt, B., Grigoriadis, A. E., Kreike, B., Natrajan, R., A’Hern, R., Tan, D. S. P., Dowsett, M., Ashworth, A., & Reis-Filho, J. S. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr071 · Cited by 131
Barton, V. N., D’Amato, N. C., Gordon, M. A., Christenson, J. L., ELIAS, A. D., & Richer, J. K. (2015) · Hormones and Cancer · doi:10.1007/s12672-015-0232-3 · Cited by 129
Babayan, A., Hannemann, J., Spötter, J., Müller, V., Pantel, K., & Joosse, S. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075038 · Cited by 129
Ellis, P., Smith, I. E., DETRE, S. I., Burton, S., Salter, J., A’Hern, R., Walsh, G., Johnston, S. R. D., & Dowsett, M. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1005933815809 · Cited by 126
Species-specific pharmacology of antiestrogens: role of metabolism.
Jordan, V. C., & Robinson, S. P. (1987) · PubMed · Cited by 125
Do 'basal-like' breast cancers really exist?
Gusterson, B. A. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2571 · Cited by 125
Zhang, B., Li, H., Riggins, R. B., Zhan, M., Xuan, J., Zhang, Z., Hoffman, E. P., Clarke, R. C., & Wang, Y. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn660 · Cited by 123
Self-citationAndruska, N. D., Zheng, X., Yang, X., Helferich, W. G., & Shapiro, D. J. (2014) · Oncogene · doi:10.1038/onc.2014.292 · Cited by 122
Rationale for targeting fibroblast growth factor receptor signaling in breast cancer
André, F., & Cortés, J. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3301-y · Cited by 113
Keeton, E. K., & Brown, M. A. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0395 · Cited by 109
Ju, Y. H., Doerge, D. R., Woodling, K. A., Hartman, J. A., Kwak, J., & Helferich, W. G. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn161 · Cited by 109
Day, J. M., Foster, P., Tutill, H. J., Parsons, M. F. C., Newman, S. P., Chander, S. K., Allan, G. M., Lawrence, H. R., Vicker, N., Potter, B. V. L., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23350 · Cited by 108
Garcia, T., Lehrer, S. P., Bloomer, W. D., et al. (1988) · Molecular Endocrinology · doi:10.1210/mend-2-9-785 · Cited by 107
Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer
Turnbull, A., Arthur, L. M., Renshaw, L., Larionov, A. A., Kay, C., Dunbier, A. K., Thomas, J. S. J., Dowsett, M., Sims, A. H., & Dixon, J. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.8963 · Cited by 106
Self-citationDeMichele, A. M., Troxel, A. B., Berlin, J. A., Weber, A. L., Bunin, G. R., Turzo, E., Schinnar, R., Burgh, D. Y., Berlin, M., Rubin, S. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0921 · Cited by 101
Hu, R., Wärri, A. M., Lu, J., Zwart, A. L., Riggins, R. B., Fang, H.-B., & Clarke, R. C. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00847-14 · Cited by 100
Self-citationGRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human disease
Booth, L. A., Roberts, J. L., Cash, D. R., Tavallai, S., Jean, S., Fidanza, A., Cruz‐Luna, T., Siembiba, P., Cycon, K. A., Cornelissen, C. N., et al. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24919 · Cited by 99
Ramanujan, S., Koenig, G. C., Padera, T. P., Stoll, B. R., & Jain, R. K. (2000) · PubMed · Cited by 97
Gu, Z., Lee, R. Y., Skaar, T. C., Bouker, K. B., Welch, J. N., Lu, J., Liu, A., Zhu, Y. J., Davis, N., Leonessa, F., et al. (2002) · PubMed · Cited by 97
Self-citationReiter, R., Wellstein, A., & Riegel, A. T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104744200 · Cited by 94
Targeting the HER/EGFR/ErbB Family to Prevent Breast Cancer
Howe, L. R., & Brown, P. H. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0334 · Cited by 93
Cook, K. L., Clarke, P. A. G., Parmar, J. H., Hu, R., Schwartz‐Roberts, J. L., Abu-Asab, M. S., Wärri, A. M., Baumann, W. T., & Clarke, R. C. (2014) · The FASEB Journal · doi:10.1096/fj.13-247353 · Cited by 92
Self-citationTumor dormancy and immunoescape
QUESNEL, B. (2008) · APMIS · doi:10.1111/j.1600-0463.2008.01163.x · Cited by 90
Manavathi, B., Samanthapudi, V. S. K., & Gajulapalli, V. N. R. (2014) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2014.00034 · Cited by 89
Shajahan‐Haq, A. N., Cook, K. L., Schwartz‐Roberts, J. L., Eltayeb, A. E., Demas, D. M., Wärri, A. M., Facey, C. O. B., Hilakivi-Clarke, L. A., & Clarke, R. C. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-239 · Cited by 89
Self-citationBurstein, H. J., Cirrincione, C., Barry, W. T., Chew, H. K., Tolaney, S. M., Lake, D. E., Ma, C. X., Blackwell, K., Winer, E. P., & Hudis, C. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.7941 · Cited by 89
Oh, A. S., List, H.-J., Reiter, R., Mani, A., Zhang, Y., Gehan, E. A., Wellstein, A., & Riegel, A. T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0354 · Cited by 87
Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight
Fuqua, S. A. W., Gu, G., & Rechoum, Y. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2847-4 · Cited by 85
A bi-faceted role of estrogen receptor β in breast cancer
Leygue, E., & Murphy, L. C. (2013) · Endocrine Related Cancer · doi:10.1530/erc-12-0389 · Cited by 83
Nehra, R., Riggins, R. B., Shajahan‐Haq, A. N., Zwart, A. L., Crawford, A. C., & Clarke, R. C. (2010) · The FASEB Journal · doi:10.1096/fj.09-138305 · Cited by 81
Self-citationDynamic Modeling of the Interaction Between Autophagy and Apoptosis in Mammalian Cells
Tavassoly, I., Parmar, J. H., Shajahan‐Haq, A. N., Clarke, R. C., Baumann, W., & Tyson, J. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.29 · Cited by 79
Self-citationChapter 14 Measuring Intratumoral Microvessel Density
Weidner, N. (2008) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(08)02814-0 · Cited by 76
The Role of Estrogen Receptor-β in Breast Cancer
Murphy, L. C., & Leygue, E. (2012) · Seminars in Reproductive Medicine · doi:10.1055/s-0031-1299592 · Cited by 76
Targeting Breast Cancer with CDK Inhibitors
Mayer, E. L. (2015) · Current Oncology Reports · doi:10.1007/s11912-015-0443-3 · Cited by 76
Is oestrogen receptor- β a predictor of endocrine therapy responsiveness in human breast cancer?
Murphy, L. C., & Watson, P. H. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01141 · Cited by 74
Wang, L., Yang, X. Y., Zhang, X., An, P., Kim, H.-J., Huang, J., Clarke, R. C., Osborne, C. K., Inman, J. K., Appella, E., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.015 · Cited by 73
Self-citationClarke, R. C., Shajahan‐Haq, A. N., Riggins, R. B., Cho, Y., Crawford, A. C., Xuan, J., Wang, Y., Zwart, A. L., Nehra, R., & Liu, M. (2009) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2008.12.023 · Cited by 71
Self-citationThe role of X-box binding protein-1 in tumorigenicity
Shajahan‐Haq, A. N., Riggins, R. B., & Clarke, R. C. (2009) · Drug News & Perspectives · doi:10.1358/dnp.2009.22.5.1378631 · Cited by 70
Self-citationVenditti, M., Iwasiow, B. M., Orr, F. W., & Shiu, R. P. C. (2002) · International Journal of Cancer · doi:10.1002/ijc.10269 · Cited by 69
du Manoir, S., Orsetti, B., Bras-Gonçalves, R., Nguyen, T.-T., Lasorsa, L., Boissière‐Michot, F., Massemin, B., Colombo, P., Bibeau, F., Jacot, W., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.11.010 · Cited by 69
Crawford, A. C., Riggins, R. B., Shajahan‐Haq, A. N., Zwart, A. L., & Clarke, R. C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008604 · Cited by 69
Self-citationNing, Y., Riggins, R. B., Mulla, J. E., Chung, H., Zwart, A. L., & Clarke, R. C. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1169 · Cited by 69
Self-citationKuske, B., Naughton, C., Moore, K. M., MacLeod, K. G., Miller, W. R., Clarke, R. C., Langdon, S. P., & Cameron, D. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01257 · Cited by 68
Self-citationBrouckaert, O., Paridaens, R., Floris, G., Rakha, E. A., Osborne, C. K., & Neven, P. (2012) · Annals of Oncology · doi:10.1093/annonc/mds238 · Cited by 62
Ojo, D., Wei, F., Liu, Y., Wang, E., Zhang, H., Lin, X., Wong, N., Bane, A. L., & Tang, D. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666150416095744 · Cited by 62
Pharmacogenetics of Tamoxifen: Who Should UndergoCYP2D6Genetic Testing?
Higgins, M. J., Rae, J. M., Flockhart, D. A., Hayes, D. F., & Stearns, V. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0014 · Cited by 58
Clarke, R. C., Shajahan‐Haq, A. N., Wang, Y., Tyson, J. J., Riggins, R. B., Weiner, L. M., Baumann, W., Xuan, J., Zhang, B., Facey, C. O. B., et al. (2011) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci.2010.073 · Cited by 57
Self-citationThoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring?
Graham, J. D., Bain, D. L., Richer, J. K., Jackson, T. A., Tung, L. W., & Horwitz, K. B. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00101-1 · Cited by 55
Dalvai, M., & Bystricky, K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011011 · Cited by 55
Schwartz‐Roberts, J. L., Shajahan‐Haq, A. N., Cook, K. L., Wärri, A. M., Abu-Asab, M. S., & Clarke, R. C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0617 · Cited by 55
Self-citationOSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing
Booth, L. A., Cazanave, S. C., Hamed, H. A., Yacoub, A., Öğretmen, B., Chen, C., Grant, S., & Dent, P. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.13.4.18877 · Cited by 54
New insights into estrogen receptor function in human breast cancer
Murphy, L. C., Cherlet, T. C., Lewis, A., Banu, Y., & Watson, P. H. (2003) · Annals of Medicine · doi:10.1080/07853890310014579 · Cited by 52
Blackburn, H. L., Ellsworth, D. L., Shriver, C. D., & Ellsworth, R. E. (2015) · Cancer Causes & Control · doi:10.1007/s10552-014-0519-7 · Cited by 50
Bartsch, R., Bagó-Horváth, Z., Berghoff, A. S., DeVries, C., Pluschnig, U., Dubsky, P. C., Rudas, M., Mader, R. M., Rottenfusser, A., Fitzal, F., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.03.002 · Cited by 50
Transfected MCF-7 cells as a model for breast cancer progression
Kern, F., McLeskey, S. W., Zhang, L., et al. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00666149 · Cited by 49
Rossi, E., Morabito, A., Maio, E. D., Rella, F. D., Esposito, G., Gravina, A., Labonia, V., Landi, G., Nuzzo, F., Pacilio, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5319 · Cited by 46
Demicheli, R., Ardoino, I., Boracchi, P., Coradini, D., Agresti, R., Ferraris, C., Gennaro, M., Hrushesky, W. J. M., & Biganzoli, E. M. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-656 · Cited by 45
What lies within: novel strategies in immunotherapy for non-small cell lung cancer.
Forde, P., Reiss, K., Zeidan, A., & Brahmer, J. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0171 · Cited by 43
Vergote, I. B., & Robertson, J. F. R. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601631 · Cited by 41
Control of cell growth, division and death: information processing in living cells
Tyson, J. J., & Novák, B. (2014) · Interface Focus · doi:10.1098/rsfs.2013.0070 · Cited by 40
Self-citationThe relevance of phosphorylated forms of estrogen receptor in human breast cancer in vivo
Murphy, L. C., Skliris, G. P., Rowan, B. G., Al-Dhaheri, M. H., Williams, C., Penner, C., Troup, S., Begic, S., Parisien, M., & Watson, P. H. (2009) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2009.01.017 · Cited by 35
A Novel ER Stress-Independent Function of the UPR in Angiogenesis
Urra, H., & Hetz, C. A. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.013 · Cited by 35
Fulvestrant for advanced breast cancer: A meta-analysis
Al-Mubarak, M., Sacher, A. G., Ocaña, A., Vera-Badillo, F., Šeruga, B., & Amir, E. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.03.004 · Cited by 35
Estrogens, Phytoestrogens, and Breast Cancer
Clarke, R. C., Hilakivi-Clarke, L. A., Cho, E., James, M. R., & Leonessa, F. (1996) · Advances in experimental medicine and biology · doi:10.1007/978-1-4613-0399-2_6 · Cited by 34
Self-citationJames, M. R., Skaar, T. C., Lee, R. Y., MacPherson, A., Zwiebel, J. A., Ahluwalia, B. S., Ampy, F. R., & Clarke, R. C. (2001) · Endocrinology · doi:10.1210/endo.142.4.8091 · Cited by 33
Self-citationChen, C., Baumann, W. T., Xing, J., Xu, L., Clarke, R. C., & Tyson, J. J. (2014) · Journal of The Royal Society Interface · doi:10.1098/rsif.2014.0206 · Cited by 32
Self-citationModelling the effect of GRP78 on anti-oestrogen sensitivity and resistance in breast cancer
Parmar, J. H., Cook, K. L., Shajahan‐Haq, A. N., Clarke, P. A. G., Tavassoly, I., Clarke, R. C., Tyson, J. J., & Baumann, W. T. (2013) · Interface Focus · doi:10.1098/rsfs.2013.0012 · Cited by 29
Self-citationSequential Hormonal Therapy for Metastatic Breast Cancer after Adjuvant Tamoxifen or Anastrozole
Carlson, R. W., & Henderson, I. C. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1025459232293 · Cited by 28
Progressive Loss of Estrogen Receptor α Cofactor Recruitment in Endocrine Resistance
Naughton, C., Macleod, K., Kuske, B., Clarke, R., Cameron, D., & Langdon, S. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0110 · Cited by 23
Self-citationRole of the Nuclear Receptor Coactivator AIB1-Δ4 Splice Variant in the Control of Gene Transcription
Chien, C. D., Kirilyuk, A., Li, J. V., Zhang, W., Lahusen, T. J., Schmidt, M. O., Oh, A. S., Wellstein, A., & Riegel, A. T. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.216200 · Cited by 23
Dormancy and spontaneous recurrence of human breast cancer in vitro.
Jm, Y., & Tarleton, A. E. (1978) · PubMed · Cited by 22
Beckwith, H. C., & Yee, D. (2014) · Endocrine Practice · doi:10.4158/ep14208.ra · Cited by 22
Koeberle, D., Ruhstaller, T., Jost, L., Pagani, O., Zaman, K., von Moos, R., Oehlschlegel, C., Crowe, S., Pilop, C., & Thuerlimann, B. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0317 · Cited by 17
Aihara, T., Yokota, I., Hozumi, Y., Aogi, K., Iwata, H., Tamura, M., Fukuuchi, A., Makino, H., Kim, R., Andoh, M., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3155-8 · Cited by 16
Clarke, R. C., Berg, H. W. V. D., Kennedy, D. G., & Murphy, R. F. (1983) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(83)90391-7 · Cited by 12
Self-citationWei, H., Chen, L., Li, J., & Yao, Z. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.04.085 · Cited by 8
[XBP-1 enhances the transcriptional activity of estrogen receptor alpha].
Ding, L., Ye, Q., Zhu, J., Yan, J., Zhong, H.-J., Wang, Z., & Huang, C. (2003) · PubMed · Cited by 3
Differential Dependency Network Analysis to Identify Topological Changes in Biological Networks
Zhang, B., Li, H., Clarke, R. C., Hilakivi-Clarke, L. A., & Wang, Y. (2010) · doi:10.1002/9783527630332.ch10 · Cited by 2
Self-citationRole of endocrine therapy in ER + /HER2 + breast cancers
Webber, V. L., & Dixon, J. M. (2013) · Breast Cancer Management · doi:10.2217/bmt.13.73 · Cited by 2
Self-citation
Cited by
PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects
Miricescu, D., Totan, A., Stanescu-Spinu, I.-I., Badoiu, S. C., Stefani, C., & Greabu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010173 · Cited by 845
The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer
Hickey, T. E., Selth, L. A., Chia, K. M., Laven-Law, G., Milioli, H. H., Roden, D., Jindal, S., Hui, M., Finlay-Schultz, J., Ebrahimie, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01168-7 · Cited by 257
Lu, Y., & Liu, W. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00913 · Cited by 119
Huang, Y., Wei, L., Hu, Y., Shao, N., Lin, Y., He, S., Shi, H., Zhang, X., & Lin, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.706733 · Cited by 82
Liu, B., Wang, T., Wang, H., Zhang, L., Xu, F., Fang, R., Li, L., Cai, X., Wu, Y., Zhang, W., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0577-5 · Cited by 73
Metadata
- Authors
- Clarke, R., Tyson, J. J., & Dixon, J. M.
- Venue
- Molecular and Cellular Endocrinology
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 418
- Pages
- 220-234
- ISSN
- 0303-7207 (ISSN-L)
- OpenAlex
- W1917948530
- Cited by
- 353
- References
- 188
- FWCI
- 20.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.